Lymphocytes

Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Friday, April 9, 2021
Branches of biology, Immune system, Lymphocytes, Natural killer cell, Biology

These data will be presented as part of the American Association for Cancer Research(AACR) 2021 Annual Meeting, which is being held virtuallyApril 10-15andMay 17-21, 2021.

Key Points: 
  • These data will be presented as part of the American Association for Cancer Research(AACR) 2021 Annual Meeting, which is being held virtuallyApril 10-15andMay 17-21, 2021.
  • We look forward to sharing data from the ongoing Phase 1 clinical trials for both programs this June.
  • These findings indicate that CD39 blockade induces proinflammatory responses, supporting future clinical studies of SRF617 for treating patients with cancer.
  • These findings indicate that IL-27 blockade regulates NK cell-mediated control of HCC and is a promising therapeutic target in liver cancer.

GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021

Retrieved on: 
Monday, March 29, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Immune system, Lymphocytes, Natural killer cell, Cytokine release syndrome, Cytokine, Cancer treatments

Dr. Miller's presentation " NK Cell Therapeutics: Off-the-shelf Strategies to Increase Activity and Specificity " highlighted the clinical power of immune engagement with Interleukin-15 (IL-15) containing TriKEs.

Key Points: 
  • Dr. Miller's presentation " NK Cell Therapeutics: Off-the-shelf Strategies to Increase Activity and Specificity " highlighted the clinical power of immune engagement with Interleukin-15 (IL-15) containing TriKEs.
  • All patients treated to date with GTB-3550 TriKE displayed no signs of any Grade of cytokine release syndrome (CRS).
  • NK cell activation increases early during treatment.This finding correlated with an increase proportion and absolute number of NK cells during treatment.
  • We believe as we continue to dose escalate GTB-3550 TriKE, more patients will experience greater clinical efficacy.

OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

Retrieved on: 
Thursday, March 25, 2021
Medicine, Clinical medicine, Medical specialties, Cancer immunotherapy, Lymphocytes, Oncology, Tumor-infiltrating lymphocytes, Immunotherapy, Melanoma, TILS, Programmed cell death protein 1, Skin cancer

The KOLs will discuss the anti-PD-1 checkpoint refractory metastatic melanoma landscape and commercial outlook:

Key Points: 
  • The KOLs will discuss the anti-PD-1 checkpoint refractory metastatic melanoma landscape and commercial outlook:
    Gregory Daniels, M.D., Ph.D., UC San Diego Health, will lead the discussion on tumor-infiltrating lymphocytes (TILs).
  • Dr. Daniels, a board-certified oncologist, coordinates care for patients with melanoma, skin cancers and head and neck cancers.
  • He is part of the Precision Immunotherapy Clinic, which offers the most promising investigational immunotherapies for many types of cancer.
  • of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute IRCCS Fondazione G. Pascale in Naples, Italy.

Enterome Receives FDA IND Clearance for EO2463, an 'OncoMimic' based Immunotherapy Targeting Liquid Tumors

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Branches of biology, Clinical medicine, Oncology, Tumor antigen, Cancer immunotherapy, Lineage markers, Lymphocytes, Immune system

EO2463 isan innovative, off-the-shelf immuno-oncology candidate that combines four OncoMimics of B lymphocytes-specific lineage markers.

Key Points: 
  • EO2463 isan innovative, off-the-shelf immuno-oncology candidate that combines four OncoMimics of B lymphocytes-specific lineage markers.
  • Theclinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in iNHL.
  • OncoMimics are peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigen (TAA) or lineage-specific markers in solid and liquid tumors, respectively.
  • "With EO2463, we are expanding the potential utility of our OncoMimics pipeline into the field of liquid tumors.

Enterome Receives FDA IND Clearance for EO2463, an 'OncoMimic' based Immunotherapy Targeting Liquid Tumors

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Branches of biology, Clinical medicine, Oncology, Tumor antigen, Cancer immunotherapy, Lineage markers, Lymphocytes, Immune system

EO2463 isan innovative, off-the-shelf immuno-oncology candidate that combines four OncoMimics of B lymphocytes-specific lineage markers.

Key Points: 
  • EO2463 isan innovative, off-the-shelf immuno-oncology candidate that combines four OncoMimics of B lymphocytes-specific lineage markers.
  • Theclinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in iNHL.
  • OncoMimics are peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigen (TAA) or lineage-specific markers in solid and liquid tumors, respectively.
  • "With EO2463, we are expanding the potential utility of our OncoMimics pipeline into the field of liquid tumors.

Vycellix to Present at Upcoming Life Science Conferences

Retrieved on: 
Tuesday, March 23, 2021
Biotechnology, Health, Genetics, Science, Research, Branches of biology, Immune system, Lymphocytes, Natural killer cell, Karolinska Institute, Life sciences, Health sciences

Vycellixs platforms were all discovered by scientists at the world-renowned Karolinska Institutet (KI) in Stockholm, Sweden.

Key Points: 
  • Vycellixs platforms were all discovered by scientists at the world-renowned Karolinska Institutet (KI) in Stockholm, Sweden.
  • For more information, please visit: www.Vycellix.com and follow our Twitter feed at: @Vycellix.
  • Vycellix is a private, immuno-centric discovery life science company, advancing the development of transformational platform technologies to enhance and optimize next-generation cell & gene-based therapies, including T cell and natural killer (NK) cell-based cancer therapies.
  • These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties.

Therapeutic Solutions International Announces Immunological Mechanism of Action of StemVacs-V™ iPSC Derived Cancer Immunotherapeutic

Retrieved on: 
Monday, March 22, 2021
Branches of biology, Medical specialties, Biology, Immune system, Immunology, Lymphocytes, Cancer immunotherapy, Immunotherapy, Virotherapy, Macrophage, Dendritic cell, Natural killer cell

ELK CITY, Idaho, March 22, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data demonstrating its StemVacs-V iPSC derived dendritic cell product stimulates two distinct immunological mechanisms responsible for its anticancer activity in animal studies.

Key Points: 
  • ELK CITY, Idaho, March 22, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data demonstrating its StemVacs-V iPSC derived dendritic cell product stimulates two distinct immunological mechanisms responsible for its anticancer activity in animal studies.
  • Additionally, examination of tumors regressing as a result of StemVacs-V treatment, revealed increased macrophage and natural killer cell infiltration.
  • "We are particularly excited by the dual mechanism of action displayed by StemVacs-V, suggesting possible advantages to other cancer therapies which usually only stimulate either adaptive or innate immunity."
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings

Retrieved on: 
Monday, March 22, 2021
Branches of biology, Medical specialties, Clinical medicine, Immune system, Lymphocytes, Cancer treatments, Natural killer cell, Immunology, Interleukins, NK-92, Lymphokine-activated killer cell

INKmune is a clinical stage proprietary tumor cell line which is administered intravenously and primes NK cells to kill otherwise resistant tumors.

Key Points: 
  • INKmune is a clinical stage proprietary tumor cell line which is administered intravenously and primes NK cells to kill otherwise resistant tumors.
  • INKmune-primed NK cells have been shown to kill a wide variety of solid and hematological cancer cells in preclinical studies.
  • INKmune-primed NK cells have a mRNA fingerprint which is fundamentally different to NK cells activated with IL-2 or IL-15.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

Acepodia to Present at the 6th Annual Innate Killer Summit

Retrieved on: 
Thursday, March 18, 2021
Immune system, Lymphocytes, Natural killer cell

A second presentation on scalable cell therapy manufacturing strategy will also be given at the conference by Acepodia senior research scientist, Sylvia Lee, M.S.

Key Points: 
  • A second presentation on scalable cell therapy manufacturing strategy will also be given at the conference by Acepodia senior research scientist, Sylvia Lee, M.S.
  • Presentation details for each conference are as follows:
    ACE1702 is Acepodias lead clinical product candidate developed from the companys natural killer (oNK) cell line and proprietary Antibody-Cell Conjugation (ACC) platform.
  • Acepodia is a privately held biotechnology company focused on eradicating cancers of all types with potent and targeted first-in-class cell therapies.
  • The companys next generation allogeneic natural killer (NK) cell therapies are based on a proprietary NK cell line (oNK) that has been selected for its potent anti-tumor activity.

ONK Therapeutics Strengthens its Cell Therapy Manufacturing Process with License for EBV-LCL Feeder Cell Line from NIH to Enhance NK Cell Expansion

Retrieved on: 
Thursday, March 18, 2021
Research, Pharmaceutical, Oncology, Other Manufacturing, Genetics, Clinical trials, Science, Chemicals, Plastics, Biotechnology, Stem cells, Manufacturing, Health, Life sciences, Branches of biology, Health sciences, Biotechnology, Immune system, Lymphocytes, Stem cells, Cell biology, Natural killer cell, Cell therapy, Therapy

Successful ex-vivo expansion of cord-derived NK cells is key to developing large cell batch sizes required to produce truly off-the-shelf engineered NK cell therapy.

Key Points: 
  • Successful ex-vivo expansion of cord-derived NK cells is key to developing large cell batch sizes required to produce truly off-the-shelf engineered NK cell therapy.
  • Expansion of up to 1,000 fold over 2-3 weeks was demonstrated with the potential for continued exponential expansion over longer periods.
  • This expansion provides a stable and consistent NK cell population that can be subsequently genetically modified and further expanded on a batch scale supportive of clinical trials of ONKs NK cell therapy candidates.
  • ONK Therapeutics Ltd is an innovative cell therapy company dedicated to developing the next generation of off-the-shelf, dual-targeted NK cell therapies targeting solid and hematological cancers.